The application of bioisosteres in drug design for novel drug discovery: Focusing on acid protease inhibitors

Expert Opinion on Drug Discovery

Volumn 7, Issue 10, 2012, Pages 903-922

  Hamada, Yoshio ^a,b   Kiso, Yoshiaki ^a,b,c  

^a KOBE GAKUIN UNIVERSITY   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^c NAGAHAMA INSTITUTE OF BIO SCIENCE AND TECHNOLOGY   (Japan)

Author keywords

secretase; Alzheimer's disease; Bioisostere; HIV; Protease inhibitor

Indexed keywords

4 CYCLOHEXYL 2 HYDROXY 3 [N [3 (MORPHOLINOCARBONYL) 2 (1 NAPHTHYLMETHYL)PROPIONYL]HISTIDYLAMINO]BUTYRIC ACID ISOPROPYL ESTER; ALISKIREN; AMPRENAVIR; ATAZANAVIR; BETA SECRETASE INHIBITOR; BIOISOSTERE; CGP 38560; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CYCLOHEXYLNORSTATINE; DARUNAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; KMI 260; KMI 420; KMI 429; KMI 541; KMI 570; KMI 596; KMI 684; LOPINAVIR; NELFINAVIR; OM 003; OM 991; OM 992; PEPSTATINE A; PHARMACEUTICAL VEHICLES AND ADDITIVES; PROTEIN INHIBITOR; PROTEINASE; PROTEINASE INHIBITOR; RENIN INHIBITOR; SAQUINAVIR; STATINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

DRUG DESIGN; DRUG METABOLISM; DRUG STRUCTURE; ELECTRON; HUMAN; MEDICAL INFORMATICS; MOLECULAR INTERACTION; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG DISCOVERY; HIV PROTEASE INHIBITORS; HUMANS; PROTEASE INHIBITORS; RENIN;

EID: 84866855651     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2012.712513     Document Type: Review

References (106)

1. Fischer E. Einfluss der configuration auf die Wirkung der Enzyme. Ber Dt Chem Ges 1894;27:2985-93
2. Friedman HL. Influence of isosteric replacements upon biological activity. NASNRS 1951;206:295-358
3. Thornber CW. Isosterism and molecular modification in drug design. Chem Soc Rev 1979;8:563-80
4. Lipinski CA. Bioisosterism in drug design. Annu Rep Med Chem 1986;21:283-91
5. Burger A. Isosterism and Bioisosterism in drug design. Prog Drug Res 1991;37:287-371
6. Patani GA, LaVoie EJ. Bioisosterism" A rational approach in drug design. Chem Rev 1996;96:3147-76
7. Lima LM, Barreiro EJ. Bioisosterism: a useful strategy for molecular modification and drug design. Curr Med Chem 2005;12:23-49
8. Patani GA, LaVoie EJ. Bioisosterism: a rational approach in drug design. Chem ReV 1996;96:3147-76
9. Thornber CW. Isosterism and molecular modification in drug design. Chem Soc ReV 1979;8:563-80
10. Sheridan RP. The most common chemical replacements in druglike compounds. J Chem Inf Comput Sci 2002;42:103-8
11. Wagener M, Lommerse JPM. The quest for bioisosteric replacements. J Chem Inf Model 2006;46:677-85
12. Meanwell NA. Synopis of some recent tactical application of bioisosteres in drug design. J Med Chem 2011;54:2529-91
13. Leung D, Abbenante G, Fairlie D. Protease inhibitors: current status and future prospects. J Med Chem 2000;43:305-41
14. Greenlee WJ. Renin inhibitors. Pharm Res 1987;4:364-74
15. Nguyen J.-T, Hamada Y, Kimura T, Kiso Y. Design of potent aspartic protease inhibitors to treat various diseases. Arch Pharm Chem Life Sci 2008;341:523-35
16. Boger J, Lohr NS, Ulm EH, et al. Novel renin inhibitors containing the amino acid statine. Nature 1983;303:81-4
17. Iizuka K, Kamijo T, Akahane K, et al. KRI-1314: Orally potent human renin inhibitors derived from angiotensinogen transition state: design, synthesis, and mode of interaction. J Med Chem 1990;10:2707-14
18. Kiso Y. Design and synthesis of HIV proteaswe inhibitors containing allophenylnorstatine as a transition-state mimic.In: Takahashi K, editor. Aspartic proteases: function, biology and biomedical implications. Olenum Press; New York: 1995. p. 413-23
19. Mimoto T, Kato R, Takaku H, et al. Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine. J Med Chem 1999;42:1789-802
20. Selkoe DJ. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 1999;399:A23-31
21. Sinha S, Lieberburg I. Cellular mechanism of b-amyloid production and secretion. Proc Natl Acad Sci USA 1999;96:11049-53
22. Hamada Y, Kiso Y. Recent progress in the drug discovery of non-peptidic BACE1 inhibitors. Expert opin Drug Discov 2009;4:391-416
23. Sinha S, Anderson JP, Barbour R, et al. Purification and cloning of amyloid precursor protein b-secretase from human brain. Nature 1999;402:637-40
24. Ghosh AK, Shin D, Downs D, et al. Design of potent inhibitors for human brain memapsin 2 (b-secretase). J Am Chem Soc 2000;122:3522-3
25. Hong L, Koelsch G, Lin X, et al. Structure of the protease domain of memapsin 2 (b-secretase) complexed with inhibitor. Science 2000;290:150-3
26. Ghosh AK, Bilcer G, Harwood C, et al. Structure-based design: potent inhibitors of human brain memapsin 2 (bsecretase). J Med Chem 2001;44:2865-8
27. Tang J, Hong L, Ghosh AK. Inhibitors of memapsin 2 and use thereof. PCT Int Appl. WO 2001000665; 2001
28. Ghosh AK, Devasamudram T, Hong L, et al. Structure-based design of cycloamide-urethane-derived novel inhibitors of human brain memapsin 2 (b-secretase). Bioorg Med Chem Lett 2005;15:15-20
29. Boyd SA, Fung AKL, Baker WR, et al. Nonpeptide renin inhibitors with good intraduodenal bioavailability and efficacy in dog. J Med Chem 1994;37:2991-3007
30. Andersen KE, Jørgensen AS, Braestrup C. Oxadiazoles as bioisosteric transformations of carboxylic functionalities. Part I. Eur J Med Chem 1994;29:393-9
31. Carroll FI, Gray JL, Abraham P, et al. 3- Aryl-2-(3′-substituted- 1′,2′,4′-oxadiazol- 5′-yl)tropane Analogues of Cocaine: affinities at the cocaine binding site at the dopamine, serotonin, and norepinephrine transporters. J Med Chem 1993;36:2886-90
32. Street LJ, Baker R, Castro JL, et al. Synthesis and serotonergic activity of 5- (oxadiazolyl)tryptamines: potent agonists for 5-HT1D receptors. J Med Chem 1993;36:1529-38
33. Dunbar PG, Durant GJ, Fang Z, et al. Design, synthesis, and neurochemical evaluation of 5-(3-Alkyl-1,2,4-oxadiazol- 5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem 1993;36:842-7
34. Adelstein GW, Yen CH, Dajani EZ, et al. 3,3-Diphenyl-3-(2-alkyl-1,3,4- oxadiazol-5-yl)propylcycloalkylamines, A novel series of antidiarrheal agents. J Med Chem 1976;19:1221-5
35. Tully WR, Gardner CR, Gillespie RJ, et al. 2-(Oxadiazolyl)- and 2-(Thiazolyl) imidazo[1,2-a]pyrimidines as agonists and inverse agonists at benzodiazepine receptors. J Med Chem 1991;34:2060-7
36. Orlek BS, Blaney FE, Brown F, et al. Comparison of azabicyclic esters and oxadiazoles as ligands for the muscarinic receptor. J Med Chem 1991;34:2726-35
37. Thompson SK, Eppley AM, Frazee JS, et al. Synthesis and antiviral activity of a novel class of HIV-1 protease inhibitors containing heterocyclic P1'-P2' amide bond isosteres. Bioorg Med Chem Lett 1994;4:2441-6
38. Kim BH, Chung YJ, Keum G, et al. A New peptide bond surrogate: 2-isoxazoline in pseudodipeptide chemistry. Tetrahedron Lett 1992;33:6811-14
39. Jones CFR, Ward GJ. Amide bond isosteres: imidazolines in pseudopeptide chemistry. Tetrahedron Lett 1988;29:3853-6
40. Clercq ED. Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. J Med Chem 1995;38:2491-517
41. Rajapakse HA, Nantermet PG, Selnick HG. Discovery of oxadiazoyl tertialy carbinamine inhibitors of b-secretase (BACE1). J Med Chem 2006;49:7270-3
42. Sankaranarayanan S, Holahan MA, Colussi D, et al. First demonstration of cerebrospinal fluid and plasma Ab Lowering with oral administration of a b-Site amyloid precursor protein-cleaving enzyme 1. Inhibitor in nonhuman primates. J Phamacol Exp Ther 2009; 328:131-40
43. Maurya SK, Gollapalli DR, Kirubakaran A, et al. Triazole inhibitors of cryptosporidium parvum inosine 5'-monophosphate dehydrogenase. J Med Chem 2009;52:4623-30
44. Narumi T, Hayashi R, Tomita K, et al. Synthesis and biological evaluation of selective CXCR4 antagonists containing alkene dipeptide isosteres. Org Biomol Chem 2010;8:616-21
45. Shuto D, Kasai S, Kimura T, et al. KMI-008, a Novel b-secretase inhibitor containing a hydroxymethylcarbonyl isostere as a transition-state mimic: design and synthesis of substrate-based octapeptides. Bioorg Med Chem Lett 2003;13:4273-6
46. Kimura T, Shuto D, Kasai S, et al. KMI-358 and KMI-370, highly potent and small-sized BACE1 inhibitors containing phenylnorstatine. Bioorg Med Chem Lett 2004;14:1527-31
47. Kimura T, Shuto D, Hamada Y, et al. Design and synthesis of highly active Alzheimer's b-secretase (BACE1) inhibitors, KMI-420 and KMI-429, with enhanced chemical stability. Bioorg Med Chem Lett 2005;15:211-15
48. Asai M, Hattori C, Iwata N, et al. The novel b-secretase inhibitor KMI-429 reduces amyloid b prptide production in amyloid precursor protein transgenic and wild-type mice. J Neurochem 2006;96:533-40
49. Kimura T, Hamada Y, Stochaj M, et al. Design and synthesis of potent b-secretase (BACE1) inhibitors with P1' carboxylic acid bioisostere. Bioorg Med Chem Lett 2006;16:2380-6
50. Hamada Y, Igawa N, Ikari H, et al. b-Secretase inhibitors: Modification at the P4 position and improvement of inhibitory activity in cultured cells. Bioorg Med Chem Lett 2006;16:4354-9
51. Hamada Y, Abdel-Rahman H, Yamani A, et al. BACE1 inhibitors: optimization by replacing the P1' residue with non-acidic moiety. Bioorg Med Chem Lett 2008;18:1649-53
52. Tagad HD, Hamada Y, Nguyen J-T, et al. Design of pentapeptidic BACE1 inhibitors with carboxylic acid bioisosteres at P1' and P4 positions. Bioorg Med Chem 2010;18:3175-86
53. Tagad HD, Hamada Y, Nguyen J-T, et al. Structure-guided design and synthesis of P1' position 1-phenylcycloalkylamine-derived pentapeptidic BACE1 inhibitors. Bioorg Med Chem 2011;19:5238-46
54. Hamada Y, Ohta H, Miyamoto N, et al. Novel non-peptidic and small-sized BACE1 inhibitors. Bioorg Med Chem Lett 2008;18:1654-8
55. Hamada Y, Ohta H, Miyamoto N, et al. Significance of interaction of BACE1-Arg235 with its ligands and design of BACE1 inhibitors with P2 pyridine scaffold. Bioorg Med Chem Lett 2009;19:2435-9
56. Satchell JF, Smith BJ. Calculation of aqueous dissociation constants of 1,2,4-triazole and tetrazole: a comparison of salvation models. Phys Chem Chem Phys 2002;4:4314-18
57. Kohara Y, Kubo K, Imamiya E, et al. Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres. J Med Chem 1996;39:5228-35
58. Ballatore C, Soper JH, Piscitelli F, et al. Cyclopentane-1,3-dione: a novel isostere for the carboxylic acid functional group. application to the design of potent thromboxane (A2) receptor antagonists. J Med Chem 2011;54:6969-83
59. Boothe J, Wilkinson R, Kushner S, et al. Synthesis of aureomycin degradation products. II J Am Chem Soc 1953;75:1732-3
60. Hiraga K. Structures of cyclopentanepolyones. Chem Pharm Bull 1965;13:1300
61. Katrusiak A. Structure of 1, 3-cyclopentanedione. Acta Crystallogr C 1990;46:1289-93
62. Katrusiak A. Structure of 2-methyl-1, 3-cyclopentanedione. Acta Crystallogr C 1989;45:1897-9
63. Dickinson RP, Dack KN, Long CJ, et al. Thromboxane modulating agents. 3. 1HImidazol- 1-ylalkyl- and 3-pyridinylalkylsubstituted 3-[2- [(arylsulfonyl)amino]ethyl] benzenepropanoic acid derivatives as dual thromboxane synthase inhibitor/ thromboxane receptor antagonists. J Med Chem 1997;40:3442-52
64. Carini DJ, Christ DD, Duncia JV, et al. The discovery and development of angiotensin II agonists. Pharm Biotechnol 1998;11:29-56
65. Soll RM, Kinney WA, Primeau J, et al. 3-Hydroxy-cyclobutene-1,2-dione: application of a novel carboxylic acid bioisostere to an in vivo active non-tetrazole angiotensin II antagonist. Bioorg Med Chem Lett 1993;3:4720-6
66. Kortum SW, Benson TE, Bienkowski MJ, et al. Potent and selective isophthalamide S2 hydroxyethylamine inhibitors of BACE1. Bioorg Med Chem Lett 2007;17:3378-83
67. Imai YN, Inoue Y, Nakanishi I, et al. Cl-p interactions in protein-ligand complexes. Protein Sci 2008;17:1129-37
68. Stubbs MT, Reyda S, Dullweber F, et al. pH-Dependent binding modes observed in trypsin crystals: lessons for structure-based drug design. Chem Bio Chem 2002;3:246-9
69. Adler M, Kochanny MJ, Ye B, et al. Crystal structures of two potent nonamidine inhibitors bound to factor Xa. Biochemistry 2002;41:15514-23
70. Choi-Sledeski YM, Kearney R, Poli G, et al. Discovery of an orally efficacious inhibitor of coagulation factor Xa which incorporates a neutral P1 ligand. J Med Chem 2003;46:681-4
71. Maignan S, Guilloteau JP, Choi-Sledeski YM, et al. Molecular structures of human factor Xa complexed with ketopiperazine inhibitors: preference for a neutral group in the S1 pocket. J Med Chem 2003;46:685-90
72. Nazare M, Will DW, Matter H, et al. Probing the subpockets of factor Xa reveals two binding modes for inhibitors based on a 2-carboxyindole scaffold: a study combining structure-activity relationship and X-ray crystallography. J Med Chem 2005;48:4511-25
73. Roehrig S, Straub A, Pohlmann J, et al. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3- oxomorpholin-4-yl)phenyl] -1,3- oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY59-7939): an oral, direct factor Xa inhibitor. J Med Chem 2005;48:5900-8
74. Tucker TJ, Brady SF, Lumma WC, et al. Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position. J Med Chem 1998;41:3210-19
75. Hamada Y, Ishiura S, Kiso Y. BACE1 Inhibitor peptides: can an infinitely small kcat value turn the substrate of an enzyme into its inhibitor? ACS Med Chem Lett 2012;3:193-7
76. Hamada Y, Tagad HD, Nishimura Y, et al. Tripeptidic BACE1 inhibitors devised by in-silico conformational structure-based design. Bioorg Med Chem Lett 2012;22:1130-5
77. Mimoto T, Hattori N, Takaku H, et al. Structure-activity relationship of orally potent tripeptide-based HIV protease inhibitors containing hydroxymethylcarbonyl isostere. Chem Pharm Bull 2000;48:1310-26
78. Kageyama S, Mimoto T, Murakawa Y, et al. In vitro anti-HIV activity of transition-state mimetic HIV protease inhibitors containing allophenylnorstatine. Antimicrob Agent Chemother 1993;37:810-17
79. Mimoto T, Imai J, Kisanuki S, et al. Kynostatin (KNI)-227 and -272, highly potent anti-HIV agents: conformationally constrained tripeptide inhibitors of HIV protease containing allophenylnorstatine. Chem Pharm Bull 1992;40:2251-3
80. Kiso Y, Matsumoto H, Mizumoto S, et al. Small dipeptide-based HIV protease inhibitors containing the hydroxymethylcarbonyl isostere as an ideal transition-state mimic. Biopolymers 1999;51:59-68
81. Kiso Y, Matsumoto H, Yamaguchi S, et al. Design of small peptidomimetic HIV-1 protease inhibitors and prodrug forms. Lett Pept Sci 1999;6:275-81
82. Mimoto T, Imai J, Tanaka S, et al. Rational design and synthesis of a novel class of active site-targeted HIV protease inhibitors containing a hydroxymethylcarbonyl isostere. Use of phenylnorstatine or allophenylnorstatine as a transition-state mimic. Chem Pharm Bull 1991;39:2465-7
83. Mimoto T, Imai J, Tanaka S, et al. KNI-102, a novel tripeptide HIV protease inhibitor containing allophenylnorstatine as a transition-state mimic. Chem Pharm Bull 1991;39:3088-90
84. Kiso Y, Yamaguchi S, Matsumoto H, et al. KNI-577, a potent small-sized HIV protease inhibitor based on the dipeptide containing the hydroxymethylcarbonyl isostere as an ideal transition-state mimic. Arch Pharm Pharm Med Chem 1998;331:87-9
85. Doi M, Ishida T, Katsuya Y, et al. KNI- 272, a highly selective and potent peptidic HIV protease inhibitor. Acta Crystallogr 2001;C 57:1333-5
86. Rajesh S, Ami E, Kimura T, et al. An expedient synthesis of Na-protected-Ltetrahydrofuranylglycine and its application in the synthesis of novel substrate based inhibitors of HIV-1 protease. Bioorg Med Chem Lett 2002;12:3615-17
87. Hamada Y, Ohtake J, Sohma Y, et al. New water-soluble prodrugs of HIV protease inhibitors based on ON intramolecular acyl migration. Bioorg Med Chem 2002;10:4155-67
88. Hamada Y, Matsumoto H, Kimura T, et al. Effect of the acyl groups on ON acyl migration in the water-soluble prodrugs of HIV-1 protease inhibitor. Bioorg Med Chem Lett 2003;13:2727-30
89. Hamada Y, Matsumoto H, Yamaguchi S, et al. Water-soluble prodrugs of dipeptide HIV protease inhibitors based on O-N intramolelcular acyl migration: design, synthesis and kinetic study. Bioorg Med Chem 2004;12:159-70
90. Doi M, Kimura T, Ishida T, et al. Rigid backbone moiety of KNI-272, a highly selective HIV protease inhibitor: methanol, acetone and dimethylsulfoxide solvated forms of 3-[3-benzyl-2-hydroxy- 9-(isoquinolin-5-yloxy)-6- methylsulfanylmethyl-5,8-dioxo-4,7- diazanonanoyl]-N-tert-butyl-1,3- thiazolidine-4-carboxamide. Acta Crystallogr B 2004;B60:433-7
91. Vega S, Kang L-W, Velazquez-Campoy A, et al. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease. Proteins Struct Funct Bioinformatics 2004;55:594-602
92. Adachi M, Ohhara T, Kurihara K, et al. Structure of HIV-1 protease in complex with potent inhibitor KNI-272 determined by high-resolution X-ray and neutron crystallography. Proc Natl Acad Sci USA 2009;106:4641-6
93. Ami E, Nakahara K, Sato A, et al. Synthesis and antiviral property of allophenylnorstatine-based HIV protease inhibitors incorporating D-cysteine derivatives as P2/P3 moieties. Bioorg Med Chem Lett 2007;17:4213-17
94. Matsumura H, Adachi M, Sugiyama S, et al. Crystallization and preliminary neutron diffraction studies of HIV-1 protease cocrystallized with inhibitor KNI-272. Acta Crystallographica 2008;F64:1003-6
95. Nakatani K, Hidaka K, Ami E, et al. Combination of Non-natural D-amino acid derivatives and allophenylnorstatine-dimethylthioproline scaffold in HIV protease inhibitors have high efficacy in mutant HIV. J Med Chem 2008;51:2992-3004
96. Velazquez-Campoy A, Luque I, Todd MJ, et al. Thermodynamic dissection of the binding energetics of KNI-272, a potent HIV-1 protease inhibitor. Protein Sci 2000;9(9):1801-9
97. Satoh T, Li M, Nguyen J-T, et al. Crystal structures of inhibitor complexes of human T-cell leukemia virus (HTLV- 1) protease. J Mol Biol 2010;401:626-41
98. Zhang M, Nguyen J-T, Kumada H-O, et al. Locking the two ends of tetrapeptidic HTLV-I protease inhibitors inside the enzyme. Bioorg Med Chem 2008;16:6880-90
99. Zhang M, Nguyen J-T, Kumada H-O, et al. Synthesis and activity of tetrapeptidic HTLV-1 protease inhibitors possessing different P3-cap moieties. Bioorg Med Chem 2008;16:5795-802
100. Nguyen J-T, Zhang M, Kumada H-O, et al. Truncation and non-natural amino acid substitution studies on HTLV-I protease hexapeptidic inhibitors. Bioorg Med Chem Lett 2008;18:366-70
101. Kimura T, Nguyen J-T, Maegawa H, et al. Chipping at large, potent human T-cell leukemia virus type 1 protease inhibitors to uncover smaller, equipotent inhibitors. Bioorg Med Chem Lett 2007;17:3276-80
102. Maegawa H, Kimura T, Arii Y, et al. Identification of peptidomimetic HTLV-1 protease inhibitors containing hydroxymethylcarbonyl (HMC) isostere as the transition state mimic. Bioorg Med Chem Lett 2004;14:5925-9
103. Available from: http://www.cresset-group. com/products/fieldstere/
104. Available from: http://syrris.com/batchproducts/ bioisostere-software
105. Available from: http://www.eyesopen. com/brood
106. Devereux M, Popelier PLA, McLay IM. Quantum Isostere Database: a Web-Based Tool Quantum Chemical Bioisosteric Replacements for Drug Design. J Chem Inf Model 2009;49:1497-513